Jason Daniel-Ulloa1, Paul A Gilbert1, Edith A Parker1. 1. The authors are with University of Iowa, College of Public Health; and University of Iowa Prevention Research Center, Cancer Prevention and Control Research Network, Iowa City.
Abstract
OBJECTIVES: To assess national differences in human papillomavirus (HPV) vaccine uptake among young adults in the United States by gender, race/ethnicity, and sexual orientation. METHODS: We tested group differences in initiation and completion of the HPV vaccine series (i.e., 3 doses) by Rao-Scott χ(2) test among 6444 respondents aged 18 to 30 years from the 2013 National Health Interview Survey. RESULTS: Among men, 5% reported receiving the HPV vaccine, with no differences in uptake by race/ethnicity or sexual orientation. By contrast, 30% of the women reported receiving the HPV vaccine, with women of color having lower odds of initiating and completing the vaccine series compared with White women. CONCLUSIONS: In the United States, HPV vaccine rates are lagging in men and show disparities among women. Increasing HPV vaccine uptake and series completion among women of color and all men may provide considerable long-term public health benefits.
OBJECTIVES: To assess national differences in human papillomavirus (HPV) vaccine uptake among young adults in the United States by gender, race/ethnicity, and sexual orientation. METHODS: We tested group differences in initiation and completion of the HPV vaccine series (i.e., 3 doses) by Rao-Scott χ(2) test among 6444 respondents aged 18 to 30 years from the 2013 National Health Interview Survey. RESULTS: Among men, 5% reported receiving the HPV vaccine, with no differences in uptake by race/ethnicity or sexual orientation. By contrast, 30% of the women reported receiving the HPV vaccine, with women of color having lower odds of initiating and completing the vaccine series compared with White women. CONCLUSIONS: In the United States, HPV vaccine rates are lagging in men and show disparities among women. Increasing HPV vaccine uptake and series completion among women of color and all men may provide considerable long-term public health benefits.
Authors: Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Harrell W Chesson; C Robinette Curtis; Julianne Gee; Joseph A Bocchini; Elizabeth R Unger Journal: MMWR Recomm Rep Date: 2014-08-29
Authors: Paul L Reiter; Noel T Brewer; Melissa B Gilkey; Mira L Katz; Electra D Paskett; Jennifer S Smith Journal: Cancer Date: 2014-06-19 Impact factor: 6.860
Authors: Perry N Halkitis; Pamela Valera; Caleb E LoSchiavo; Stephen E Goldstone; Maria Kanztanou; Anthony J Maiolatesi; Danielle C Ompad; Richard E Greene; Farzana Kapadia Journal: AIDS Patient Care STDS Date: 2019-04 Impact factor: 5.078
Authors: Madina Agénor; Ashley E Pérez; Sarah M Peitzmeier; Jennifer Potter; Sonya Borrero Journal: J Womens Health (Larchmt) Date: 2018-06-29 Impact factor: 2.681
Authors: James L Klosky; Melissa M Hudson; Yanjun Chen; James A Connelly; Karen Wasilewski-Masker; Can-Lan Sun; Liton Francisco; Laura Gustafson; Kathryn M Russell; Gina Sabbatini; Jessica S Flynn; Jocelyn M York; Anna R Giuliano; Leslie L Robison; F Lennie Wong; Smita Bhatia; Wendy Landier Journal: J Clin Oncol Date: 2017-08-24 Impact factor: 44.544
Authors: Kaan Z Apaydin; Holly B Fontenot; Derri Shtasel; Sannisha K Dale; Christina P C Borba; Christopher S Lathan; Lori Panther; Kenneth H Mayer; Alex S Keuroghlian Journal: Vaccine Date: 2018-05-16 Impact factor: 3.641
Authors: Eshan U Patel; M Kate Grabowski; Anna L Eisenberg; Zoe R Packman; Patti E Gravitt; Aaron A R Tobian Journal: J Infect Dis Date: 2018-06-05 Impact factor: 5.226